CTOs on the Move

Colonial Senior Service

www.colonialseniors.org

 
Colonial Senior Service is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Hamilton, OH. To find more information about Colonial Senior Service, please visit www.colonialseniors.org
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

The ALARIS Group

The ALARIS Group is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mosaic

Mosaic is a whole-person healthcare organization reaching across 11 states and providing supports to more than 4,500 people. Services empower people with disabilities, mental and behavioral health needs and autism, as well as aging adults to live their best life. Mosaic is an affiliated social ministry organization of the Evangelical Lutheran Church in America and a member of Lutheran Services in America. Mosaic is a nonprofit 501(c)(3) organization.

Pain Management Service

Pain Management Service is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.